中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.015 seconds)

    COMPOSITION FOR PREVENTING OR TREATING FRACTURE OR OSTEOPOROSIS USING SLIT-ROBO SYSTEM
    2.
    发明申请
    COMPOSITION FOR PREVENTING OR TREATING FRACTURE OR OSTEOPOROSIS USING SLIT-ROBO SYSTEM 有权
    用SLIT-ROBO系统预防或治疗骨折或骨质疏松的组合物

    公开(公告)号：US20150175673A1

    公开(公告)日：2015-06-25

    申请号：US14408275

    申请日：2013-06-14

    Applicant: THE ASAN FOUNDATION

    Inventor： Jung-Min Koh ,  Ghi Su Kim ,  Seung Hun Lee ,  Young-Sun Lee ,  Beom-Jun Kim

    IPC: C07K14/47 ,  A23L1/305 ,  G01N33/50

    CPC classification number: C07K14/47 ,  A23L33/195 ,  A23V2002/00 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4702 ,  C07K14/70503 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2500/10 ,  G01N2800/108

    Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

    Abstract translation: 用于预防或治疗骨折或骨质疏松症的药物组合物包括作为活性成分的选自由狭缝1，狭缝2，裂缝3，robo1，robo2和vilse组成的组的基因或所述基因的表达蛋白质。 用于预测骨折或骨质疏松症发生风险的标记物组合物包括蛋白质。 用于预测骨折或骨质疏松症发生风险的试剂盒包括特异性结合蛋白质的抗体。 用于预测骨折或骨质疏松症发生风险的信息提供方法包括使用特异性结合蛋白质的抗体通过抗原 - 抗体结合反应来测定狭缝蛋白的表达水平。 狭缝3可能在细胞和动物模型中增加骨形成并减少骨重吸收，并与骨质疏松症的发生率呈负相关。

    MARKER COMPOSITION COMPRISING S1P PROTEIN FOR PREDICTION OF RISK IN OSTEOPOROTIC FRACTURE AND OSTEOPOROSIS
    4.
    发明申请
    MARKER COMPOSITION COMPRISING S1P PROTEIN FOR PREDICTION OF RISK IN OSTEOPOROTIC FRACTURE AND OSTEOPOROSIS 审中-公开
    包含S1P蛋白质的标记物组合物，用于预测OSTEOPOROTIC FRACTURE和OSTEOPOSOSIS的风险

    公开(公告)号：US20130331282A1

    公开(公告)日：2013-12-12

    申请号：US13865688

    申请日：2013-04-18

    Applicant: THE ASAN FOUNDATION

    Inventor： Jung Min Koh ,  Ghi Su Kim ,  Seung Hun Lee ,  Beom Jun Kim

    IPC: G01N33/92 ,  C07K16/18 ,  C07K14/47

    CPC classification number: G01N33/92 ,  C07K14/47 ,  C07K16/18 ,  G01N33/6893 ,  G01N2405/08 ,  G01N2800/108

    Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.

    Abstract translation: 本文公开了包含鞘氨醇1-磷酸（S1P）蛋白质并可用于预测骨折或骨质疏松症风险的标记物组合物; 包括特异性结合S1P蛋白并可用于预测骨折或骨质疏松症风险的抗体的试剂盒; 以及可用于获得允许预测骨折或骨质疏松症风险的信息的方法，并且包括通过测量S1P特异性抗体与S1P蛋白的结合来测量S1P蛋白浓度。 本文公开的S1P蛋白质在具有骨折的个体中高度表达，而不管其骨矿物质密度如何。 因此，作为骨折或骨质疏松症风险的生物标志物可能是有用的。

Patent Agency Ranking